News | Digital Pathology | October 18, 2021

Landmark study to demonstrate reduction of standard next-day histology testing to less than 10 minutes

Histolix, a leading developer of direct-to-digital read pathology solutions, announced it has launched a groundbreaking clinical trial to prove equivalency of its digital technology to current gold standard pathology testing.

Benign breast in collagenous stroma with adipose stroma (top right). Lobular structure, capillaries, and surrounding fibroblast are easily recognized. Image courtesy of Histolix

October 18, 2021 — Histolix, a leading developer of direct-to-digital read pathology solutions, announced it has launched a groundbreaking clinical trial to prove equivalency of its digital technology to current gold standard pathology testing. The company’s direct-to-digital read solution is designed to reduce today’s labor-intensive slide-based pathology preparation and reads, which can take in excess of eight hours to produce, to less than 10 minutes. Leading pathology experts believe the Histolix technology could provide a radical new approach to the preparation of biopsy specimens.

“The Histolix technology heralds a radically new approach to the preparation of the images required by pathologists to interpret biopsy specimens,” said Allen Gown, M.D., former professor at the University of Washington Medical Center and founder of PhenoPath Laboratories. “Since its origins in the 19th century, pathology has been constrained by a laborious and time-consuming process of fixation, dehydration, paraffinization, rehydration and staining requiring skilled technologists and expensive equipment. Histolix technology promises to dramatically reduce the time required to prepare these images and simultaneously permits a direct-to-digital pathologic evaluation framework, permitting pathology to emulate radiology in rapid evaluation and dissemination of biopsy findings.”

Gown further believes Histolix generates digital images suitable for pathologic evaluation accessible to a wide range of users, including satellite lab facilities, veterinary laboratories and resource-constrained laboratories all over the world.

Histolix plans to release the findings of its initial clinical validation study comparing direct-to-digital technology diagnosis versus standard FFPE tissue section H&E slides by the end of the year. The comparison will show diagnostic accuracy of Histolix imaging in under 10-minute acquisition of over 20 tissue types. A follow-on trial in 2022 will include lumpectomy intra-operative margin assessment, targeting up to 30 percent of the re-surgical procedures that occur today in breast cancer and other surgeries due to limitations of today’s standard, frozen section techniques for tissue margin analysis.

“After decades of minimal change to the WSI market, it's exciting to see a technology such as Histolix impacting direct read of tissue at point-of-care and in the operational suites,” said Rob Royea, president and CEO of Histolix. “Histolix is proving the viability of this technology with expert third party pathologists reviewing and providing diagnosis for 100 surgical cases from both Histolix images and in standard glass slide whole slide images, in random order with a “washout” between reads. We are excited to partner with renowned pathologists from UC Davis who founded this technology and guide the clinical validation trials. It is also our honor to have Dr. Gown join us in this historic endeavor.”

The pathology market is immense with over 4.5M biopsies performed per year and over 1.2M surgeries accelerating at a six percent rate annually. The global cancer biopsy market is projected to reach $33B USD by 2027. Histolix direct-to-digital read from fresh tissue across multiple tissue types has the potential to replace a sizable percentage of current pathology processes while significantly decreasing headcount and tissue handling cost, along with the possible elimination of up to 30 percent of non-necessary repeated surgical procedures.

“With today's embedded cost of whole slide imaging including redundant processes, transportation and delayed diagnosis, Histolix could significantly impact cost reduction, enable short term treatment and reduce personal trauma due to delayed diagnosis,” concluded Royea. “Moreover, Histolix technology will enable expert telepathology and AI molecular level assessment globally ensuring peace of mind for diagnosticians and patients alike. We look forward to publicizing our clinical trials in the near future.”

For more information:

Related Content

News | Stereotactic Body Radiation Therapy (SBRT)

October 1, 2023 — Older adults diagnosed with kidney tumors that are not suitable for surgery may benefit from targeted ...

Time October 01, 2023
News | Prostate Cancer

September 29, 2023 — People with intermediate risk, localized prostate cancer can be treated as effectively using fewer ...

Time September 29, 2023
News | Computed Tomography (CT)

September 29, 2023 —Nano-X Imaging, an innovative medical imaging technology company, today announced that HealthCCSng ...

Time September 29, 2023
News | Breast Imaging

September 27, 2023 — Researchers at Weill Cornell Medicine have discovered that radiation therapy combined with two ...

Time September 27, 2023
News | Mammography

September 26, 2023 — Artificial intelligence(AI) and machine learning tools have received a lot of attention recently ...

Time September 26, 2023
News | Artificial Intelligence

September 20, 2023 — Medical imaging artificial intelligence (AI) company has announced that the results ...

Time September 20, 2023
Sponsored Content | Case Study | Radiology Imaging | By Tim Hodson

In June, the Philips Radiology Experience Tour hit the road to provide healthcare professionals with an opportunity to ...

Time September 19, 2023
News | Artificial Intelligence

September 11, 2023 — Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, is ...

Time September 11, 2023
News | PET-CT

September 8, 2023 — Positron Corporation, a leading molecular imaging medical device company, is pleased to announce ...

Time September 08, 2023
Feature | Radiology Education | By Melinda Taschetta-Millane

ITN’s award-winning editorial team delivers industry trends and technology information to the professionals who make ...

Time August 28, 2023
Subscribe Now